Last reviewed · How we verify
Cardiovascular Agents
Cardiovascular Agents is a Cardiovascular Agents Small molecule drug developed by UMC Utrecht. It is currently in Phase 1 development. Also known as: Acetylsalicylic acid 80 mg, Simvastatin 40 mg, Lisinopril 10 mg, Hydrochlorothiazide 12,5 mg.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cardiovascular Agents |
|---|---|
| Also known as | Acetylsalicylic acid 80 mg, Simvastatin 40 mg, Lisinopril 10 mg, Hydrochlorothiazide 12,5 mg |
| Sponsor | UMC Utrecht |
| Drug class | Cardiovascular Agents |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SMILE Trial - Imaging Sub-Study
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Body Composition Assessment in Transgender Population.
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cardiovascular Agents CI brief — competitive landscape report
- Cardiovascular Agents updates RSS · CI watch RSS
- UMC Utrecht portfolio CI
Frequently asked questions about Cardiovascular Agents
What is Cardiovascular Agents?
Who makes Cardiovascular Agents?
Is Cardiovascular Agents also known as anything else?
What drug class is Cardiovascular Agents in?
What development phase is Cardiovascular Agents in?
Related
- Drug class: All Cardiovascular Agents drugs
- Manufacturer: UMC Utrecht — full pipeline
- Also known as: Acetylsalicylic acid 80 mg, Simvastatin 40 mg, Lisinopril 10 mg, Hydrochlorothiazide 12,5 mg